Skip to main content

Table 2 Postoperative adjuvant immunotherapy trials for HCC

From: Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma

Identifier No. Interventions Setting Primary outcome
NCT03859128 (JUPITER 04) Toripalimab or placebo Phase 2, 3 RFS
NCT03383458 (CheckMate 9DX) Nivolumab or placebo Phase 3 RFS
NCT03867084 (KEYNOTE-937) Pembrolizumab Phase 3, Double-blinded, Placebo controled RFS, OS
NCT04639180 Camrelizumab plus Apatinib   
NCT04102098 (IMbrave050) Atezolizumab plus Bevacizumab Phase 3, open label, two arms (versus active surveillence) RFS
NCT03847428 (EMERALD-2) Durvalumab plus bevacizumab or durvalumab monotherapy or placebo Phase 3, randomized, double-blind, placebo-controlled RFS
NCT04418401 (CISLD-8) Donafenib plus any anti-PD-1 antibody Phase 1 1-year RFS
NCT04233840 Nivolumab and Ropeginterferon alfa-2b Phase I/II Open Label RFS